Global Immunotherapy Drugs Market Size Study, by Type of Drugs (Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, Others) by Therapy Area (Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Others) by End-Use (Hospitals, Clinics, Others) by Regional Forecasts 2018-2025

May 2019 | 200 pages | ID: GA0A3860719EN
Bizwit Research & Consulting LLP

Abstracts

Global immunotherapy drugs market is valued approximately USD billion in 2017 and is anticipated to grow with a healthy growth rate of more than 15.2% over the forecast period 2018-2025. Key driving factors of the market are increasing prevalence of life-style oriented diseases, early drug approval processes coupled with increasing adoption of targeted therapies. However, high cost of treatment is expected to hamper the market growth over the forecast period. Increasing prevalence of cancer is one of the significant factors which is driving global immunotherapy drugs market during the forecast period. According to the World Cancer Report, Cancer rates are expected to increase by 50% in the year 2020 reaching a total of 15 million patients.

Regionally, the global immunotherapy market is dominated by North America region valued about $45.9 billion in 2017 that is estimated to reach about $115.9 billion by 2025. North America is followed by Europe, holding the second highest position in global immunotherapy drugs market with 29.0 billion revenues in 2016. These regions account for the highest prevalence of cancer. Furthermore, increasing number of clinical trials and drug approvals in these regions are fueling the market growth. The growth of European market is driven by increasing R&D investments from both public and private sectors. Furthermore, significant growth in drug approvals by European Medicines Agency and strong presence of key players is driving the market growth. However, Asia Pacific is anticipated to grow at the highest CAGR of 18.0% over the forecast period. Rising prevalence of cancers and extensive R&D towards the development of low-cost treatment is anticipated to drive significant opportunities in the APAC immunotherapy drugs market.
On the basis of end-use, the global immunotherapy drugs market is segmented into hospitals, clinics and others. Currently, hospitals segment holds the largest revenue share. Global immunotherapy drugs market in hospitals valued at USD 68.3 billion in 2017 and is anticipated to reach USD 202.3 billion by 2025 growing at a CAGR of 14.5%.

Market player included in this report are:
F.Hoffmann-LA Roche AG
Merck & Co., Inc.
Novartis International AG
Johnson & Johnson (A Parent Company of Jannssen Biotech, Inc.)
GlaxoSmithKline PLC
Amgen Inc.
AbbVie
AstraZeneca
Bristol-Mysers Squibb
ELI Lilly & Company

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type of Drugs:

Monoclonal Antibodies
Adult Vaccines
Checkpoint Inhibitors
Interferons Alpha & Beta
Interleukins
Other Drugs

By Therapy Area:

Cancer
Autoimmune & Inflammatory Diseases
Infectious Diseases
Other Therapy Area

By End-Use:

Hospitals
Clinics
Other End Users

By Regions:

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
• Asia Pacific
  • China
  • India
  • Japan
• Latin America
  • Brazil
  • Mexico
• Rest of the World

Furthermore, years considered for the study are as follows:

• Historical year – 2015, 2016
• Base year – 2017
• Forecast period – 2018 to 2025

Target Audience of the Global Immunotherapy Drugs Market in Market Study:

Key Consulting Companies & Advisors

• Large, medium-sized, and small enterprises
• Venture capitalists
• Value-Added Resellers (VARs)
• Third-party knowledge providers
• Investment bankers
• Investors

Contents

CHAPTER 1. EXECUTIVE SUMMARY

1.1. Market Snapshot
1.2. Key Trends
1.3. Global & Segmental Market Estimates & Forecasts, 2015-2025 (USD Million)
  1.3.1. Immunotherapy Drugs Market, by Type, 2015-2025 (USD Million)
  1.3.2. Immunotherapy Drugs Market, by Therapy Area, 2015-2025 (USD Million)
  1.3.3. Immunotherapy Drugs Market, by End-use, 2015-2025 (USD Million)
  1.3.4. Immunotherapy Drugs Market, by Region, 2015-2025 (USD Million)
1.4. Estimation Methodology
1.5. Research Assumption

CHAPTER 2. GLOBAL IMMUNOTHERAPY DRUGS MARKET DEFINITION AND SCOPE

2.1. Objective of the Study
2.2. Market Definition & Scope
  2.2.1. Industry Evolution
  2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates

CHAPTER 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET DYNAMICS

3.1. See Saw Analysis
  3.1.1. Market Drivers
  3.1.2. Market Challenges
  3.1.3. Market Opportunities

CHAPTER 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET INDUSTRY ANALYSIS

4.1. Porter’s 5 Force Model
  4.1.1. Bargaining Power of Buyers
  4.1.2. Bargaining Power of Suppliers
  4.1.3. Threat of New Entrants
  4.1.4. Threat of Substitutes
  4.1.5. Competitive Rivalry
  4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.2. PEST Analysis
  4.2.1. Political Scenario
  4.2.2. Economic Scenario
  4.2.3. Social Scenario
  4.2.4. Technological Scenario
4.3. Key Buying Criteria (On Demand)
4.4. Regulatory Framework (On Demand)
4.5. Investment Vs Adoption Scenario (On Demand)
4.6. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE

5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Immunotherapy Drugs Market, Sub Segment Analysis
  5.3.1. Monoclonal Antibodies
    5.3.1.1. Market estimates & forecasts, 2015-2025 (USD Million)
    5.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)
  5.3.2. Adult Vaccines
    5.3.2.1. Market estimates & forecasts, 2015-2025 (USD Million)
    5.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)
  5.3.3. Checkpoint Inhibitors
    5.3.3.1. Market estimates & forecasts, 2015-2025 (USD Million)
    5.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)
  5.3.4. Interferons Alpha & Beta
    5.3.4.1. Market estimates & forecasts, 2015-2025 (USD Million)
    5.3.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)
  5.3.5. Interleukins
    5.3.5.1. Market estimates & forecasts, 2015-2025 (USD Million)
    5.3.5.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)
  5.3.6. Others Drugs
    5.3.6.1. Market estimates & forecasts, 2015-2025 (USD Million)
    5.3.6.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)

CHAPTER 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA

6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Immunotherapy Drugs Market, Sub Segment Analysis
  6.3.1. Cancer
    6.3.1.1. Market estimates & forecasts, 2015-2025 (USD Million)
    6.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)
  6.3.2. Autoimmune & Inflammatory Diseases
    6.3.2.1. Market estimates & forecasts, 2015-2025 (USD Million)
    6.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)
  6.3.3. Other Therapy Areas
    6.3.3.1. Market estimates & forecasts, 2015-2025 (USD Million)
    6.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)

CHAPTER 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END-USE

7.1. Market Snapshot
7.2. Market Performance - Potential Model
7.3. Immunotherapy Drugs Market, Sub Segment Analysis
  7.3.1. Hospital
    7.3.1.1. Market estimates & forecasts, 2015-2025 (USD Million)
    7.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)
  7.3.2. Clinics
    7.3.2.1. Market estimates & forecasts, 2015-2025 (USD Million)
    7.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)
  7.3.3. Other
    7.3.3.1. Market estimates & forecasts, 2015-2025 (USD Million)
    7.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Million)

CHAPTER 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGIONAL ANALYSIS

8.1. Immunotherapy Drugs Market, Regional Market Snapshot (2015-2025)
8.2. North America Immunotherapy Drugs Market Snapshot
  8.2.1. U.S.
    8.2.1.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.2.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.2.1.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.2.1.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
  8.2.2. Canada
    8.2.2.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.2.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.2.2.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.2.2.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
8.3. Europe Immunotherapy Drugs Market Snapshot
  8.3.1. U.K.
    8.3.1.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.3.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.3.1.3. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.3.1.4. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
  8.3.2. Rest of Europe
    8.3.2.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.3.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.3.2.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.3.2.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
8.4. Asia Immunotherapy Drugs Market Snapshot
  8.4.1. China
    8.4.1.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.4.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.4.1.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.4.1.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
  8.4.2. India
    8.4.2.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.4.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.4.2.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.4.2.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
  8.4.3. Japan
    8.4.3.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.4.3.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.4.3.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.4.3.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
  8.4.4. Rest of Asia Pacific
    8.4.4.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.4.4.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.4.4.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.4.4.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
8.5. Latin America Immunotherapy Drugs Market Snapshot
  8.5.1. Brazil
    8.5.1.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.5.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.5.1.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.5.1.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
  8.5.2. Mexico
    8.5.2.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.5.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.5.2.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.5.2.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
8.6. Rest of The World
  8.6.1. South America
    8.6.1.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.6.1.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.6.1.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.6.1.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)
  8.6.2. Middle East and Africa
    8.6.2.1. Market estimates & forecasts, 2015-2025 (USD Million)
    8.6.2.2. Type breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.6.2.3. Therapy Area breakdown estimates & forecasts, 2015-2025 (USD Million)
    8.6.2.4. End-use breakdown estimates & forecasts, 2015-2025 (USD Million)

CHAPTER 9. COMPETITIVE INTELLIGENCE

9.1. Company Market Share (Subject to Data Availability)
9.2. Top Market Strategies
9.3. Company Profiles
  9.3.1. F.Hoffmann-LA Roche AG
    9.3.1.1. Overview
    9.3.1.2. Financial (Subject to Data Availability)
    9.3.1.3. Product Summary
    9.3.1.4. Recent Developments
  9.3.2. Merck & Co., Inc.
  9.3.3. Novartis International AG
  9.3.4. Johnson & Johnson (A Parent Company of Jannssen Biotech, Inc.)
  9.3.5. GlaxoSmithKline PLC
  9.3.6. Amgen Inc.
  9.3.7. AbbVie
  9.3.8. AstraZeneca
  9.3.9. Bristol-Mysers Squibb
  9.3.10. ELI Lilly & Company

CHAPTER 10. RESEARCH PROCESS

10.1. Research Process
  10.1.1. Data Mining
  10.1.2. Analysis
  10.1.3. Market Estimation
  10.1.4. Validation
  10.1.5. Publishing
  10.1.6. Research Assumption